Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said. Pfizer has said it has 180,000 treatment courses ready to ship this year. The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19. Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval.

Source: Philippine Daily Inquirer December 23, 2021 03:29 UTC